Sanofi - American Depositary Shares (NQ:SNY)

39.92 -0.75 (-1.84%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 15, 2025

From Pomerantz LLP

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)

June 13, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SANOFI-ADR (NASDAQ:SNY) - A Reliable Dividend Stock with Strong Fundamentals ↗

June 05, 2025

Via Chartmill

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

June 12, 2025

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

Via MarketBeat

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial ↗

June 11, 2025

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 10, 2025

From Pomerantz LLP

Via GlobeNewswire

American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance ↗

June 10, 2025

The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule.

Via Benzinga

Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. ↗

June 09, 2025

A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.

Via Investor's Business Daily

Topics Government

June 09, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season ↗

June 09, 2025

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Via Benzinga

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗

June 08, 2025

Via Benzinga

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗

June 06, 2025

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

Via Benzinga

Topics Bankruptcy

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 06, 2025

From Pomerantz LLP

Via GlobeNewswire

RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts ↗

June 06, 2025

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health...

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasdaq – VIGL)

June 04, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response ↗

June 02, 2025

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.

Via Benzinga

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies ↗

June 02, 2025

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Via Stocktwits

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals ↗

June 02, 2025

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

Via Benzinga

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout ↗

June 02, 2025

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Via Benzinga

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗

June 02, 2025

Via Benzinga

US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert ↗

June 02, 2025

U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket.

Via Benzinga

Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday ↗

June 02, 2025

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗

May 31, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure ↗

May 30, 2025

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Via Investor's Business Daily

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data ↗

May 30, 2025

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Via Benzinga

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

May 30, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children ↗

May 27, 2025

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.

Via Benzinga

Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive ↗

May 27, 2025

According to Reuters, operations at the new facility are expected to begin by the end of 2027.

Via Stocktwits

SANOFI-ADR (NASDAQ:SNY) – A Pharmaceutical Stock With Undervalued Potential ↗

May 26, 2025

SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector.

Via Chartmill

Analysts Think These Stocks Could More Than Double in Value

May 23, 2025

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

Via MarketBeat

Topics World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.